HAVCR2 and neoplasm: To this end, we compared previously used injection of the ODN1826 plus α-GalCer mixture (supplemented with anti-Tim-3 in some groups) on days of immunization (i.e., 3 doses delivered 3, 6 and 10 days after inoculation of tumor cells, Figure 2A) with injection of 5 doses on days 3, 6, 10, 13 and 17 (Figure 2B) and 3 doses on days 10, 13 and 17 (Figure 2C).